Explore evidence

90 %From 1st July 2022 to 30th June 2023, 90% of women with visual inspection with acetic acid (VIA) positive lesions received appropriate treatment.

Kenyacancer du col de l'utérusobserved 1st July 2022 to 30th June 2023published 2025BMC women's healthPubMeddocument of 8 observations

49.7 %Ever-screening for cervical cancer was reported by 49.7% of the 736 Kenyan respondents.

Kenyacancer du col de l'utérusobserved 2022-2023published 2025BMC public healthPubMeddocument of 8 observations

100 %Squamous cell carcinoma was present in 100% of people living with HIV and 88.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations

24 %24% of women aged ≥25 years attending infant immunization clinics in Kenya reported a history of cervical cancer screening.

Kenyacancer du col de l'utérusobserved 2018 and 2019published 2025BMC women's healthPubMeddocument of 8 observations

57 %The 1 and 2-year survival probability after diagnosis of cervical cancer was 57% and 45% respectively.

Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations

28 %Clinics that did not report cervical cancer screening had 28% (9/32) with at least one provider trained to perform cervical cancer screening.

Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2

49 %The largest share of guideline-adherent cancer-directed therapy was observed in Nairobi (49%).

Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718

13.8 %In Kenya, only 13.8% of women participate in cervical cancer screening programs.

Kenyacancer du col de l'utéruspublished 2026BMC research notesPubMeddocument of 7 observations

16.3 %Cervical cancer screening was reported in 16.3% of HIV-uninfected women attending infant immunization clinics in Kenya.

Kenyacancer du col de l'utérusobserved 2018 and 2019published 2025BMC women's healthPubMeddocument of 8 observations

70 %HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases.

Kenyacancer du col de l'utéruspublished 2022Frontiers in public healthPubMeddocument of 4 observations

87 %Only 87% (33) of clinics that reported performing cervical cancer screening had dependable access to speculums.

Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2

9,000 casesAnnual vaccine supply disruptions would avert less than 9,000 cervical cancer cases compared with a 1-dose strategy.

Kenyacancer du col de l'utérusPubMeddocument of 6 observations

45.3 %During a national phone survey in Kenya, 45.3% of male respondents had discussed cervical cancer with their wife/partner.

Kenyacancer du col de l'utéruspublished 2026Cancer epidemiology, biomarkers & prevention : a publication of the American Association fPubMeddocument of 5 observations

40 %Lymphovascular space invasion (LVSI) was the predominant intermediate-risk feature, occurring in 40.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations

16 %The proportion of HIV-infected women screened for cervical cancer increased from 16% to 57% in the intervention arm after the nurse-led health education intervention.

Kenyacancer du col de l'utéruspublished 2025Asian Pacific journal of cancer prevention : APJCPPubMeddocument of 5 observations

Cervical cancer is the second most common cancer after breast cancer among women in Kenya.

Kenyacancer du col de l'utéruspublished 2023BMC cancerPubMeddocument of 12 observations

48 %Among women attending large HIV care and treatment programs across Kenya between June and September 2016, 804 (48%) of those who reported ever being screened were screened within the last 12 months.

Kenyacancer du col de l'utérusobserved June and September 2016published 2022International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument of 3 observations

16 %In Kenya, the estimated cervical cancer screening uptake among women aged 30–49 is 16%.

Kenyacancer du col de l'utéruspublished 2023Implementation science : ISPubMeddocument of 2 observations

17 %The cervical cancer screening rate in Kenya currently stands at 16-18%.

Kenyacancer du col de l'utéruspublished 2024BMC women's healthPubMeddocument of 3 observations

16,000 casesA gradual scale-up of the current 2-dose quadrivalent vaccine (4vHPV) program would avert an additional 16,000 cervical cancer cases compared with maintaining current program performance.

Kenyacancer du col de l'utérusPubMeddocument of 6 observations

173,000 casesCompared with no vaccination, maintaining current program performance would avert approximately 173,000 cervical cancer cases across 2019 to 2100.

Kenyacancer du col de l'utérusobserved 2019 to 2100PubMeddocument of 6 observations

10.8 %Across the 19 facilities, 10.8% of the women enrolled in care at the hospital were screened for cervical cancer during the data collection period.

Kenyacancer du col de l'utérusobserved September 2021 to September 2022published 2025JCO global oncologyPubMeddocument of 3 observations

34.8 %Thirty-four point eight percent (34.8%) of the respondents obtained information about cervical cancer from health talks.

Kenyacancer du col de l'utéruspublished 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations

69.2 %Lymphovascular space invasion (LVSI) was the predominant intermediate-risk feature, occurring in 69.2% of people living with HIV and 40.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobserved 2014–2023published 2026BMC cancerPubMeddocument of 16 observations

2.5 %Mauritius had a constant annual 2.5% decline in cervical cancer incidence.

Kenyacancer du col de l'utéruspublished 2020British journal of cancereurope_pmcdocument of 5 observations